Drug intelligence / Profile preview

Teflorect

Development stage: Unknown
Lead developer: Gynavista
Modality: Small Molecules
Administration: Oral

Overview

**Teflorect** is a Gynavista fixed-dose oral tablet containing tadalafil 10 mg and dapoxetine 30 mg. Tadalafil is a selective phosphodiesterase type 5 inhibitor that enhances nitric-oxide-mediated penile smooth-muscle relaxation and blood flow during sexual stimulation; dapoxetine is a short-acting selective serotonin reuptake inhibitor used to improve ejaculatory control. The product is marketed for erectile dysfunction and premature ejaculation and is listed by Gynavista in its male-infertility portfolio. ([apollopharmacy.in](https://www.apollopharmacy.in/te/medicine/teflorect-new-10mg-30mg-tablet))

Brand names: TeflorectTeflorect New

Targets

SERT (Sodium-dependent serotonin transporter)PDE5 (Phosphodiesterase 5A)

Beyond the preview

Go deeper on Teflorect.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Teflorect.

Explore the full profile